Quintiles Library

Featured Fact Sheet

Retain patients in real-world studies
A patient-centric solution to provide stronger evidence Collecting patient-reported evidence for your observational studies is critical for demonstrating the safety and effectiveness of your therapies. To capture that data and produce a comprehensive picture of health outcomes, you need to engage patients over time and assist researchers in improving compliance. ...
Show Filters
Presentation
This presentation will describe the use of Advanced Simulation Engineering (ASE) to develop and add enhancements to Quintiles Infosario® Design, a novel approach to design and plan clinical development programs and trials. ASE offers the following advantages: Rapid, iterative, design to build superior solutions Allows business, IT, and end-users to share an understanding of a software solution The ability to determine the feasibility of a function, scenario or solution without the large investment of coding, developers and infrastructure Provides a visual, validated by stakeholders, that communicates to developers what should be produced in terms of UI and functionality. Addresses perceived shortcomings in a traditional UX approach of not delivering actionable...
Explore More
Brochure
ステークホルダーが規制や償還、処方に関わる決定を裏付けるエビデンスをさらに求める中、リアルワールドと市販後調査が製品の成功に欠かせないものとなってきています。新規の試験は、デザインをはじめ、運営、分析、品質保証について新しい科学的水準を満たさなければなりません。 経験豊富な戦略的研究とテクノロジーを提供するパートナーとして、クインタイルズは、お客様のニーズを満たす高品質のプログラムをカスタマイズしてデザインし実施するお手伝いをします。 コンテンツは日本語です。
Read More
Brochure
最新技術とパートナーシップによって患者データへの新たなアクセスが開発されるに伴い、リアルワールド条件下で製品の有効性と安全性を実証できるエビデンスの作成がこれまでになく重要になっています。 このようなエビデンスを提供してステークホルダーのニーズを満たすことができるのが、観察研究と患者レジストリです。 リアルワールドプログラムでは治験とは異なる設計や実施課題がもたらされるため、治験とは異なる専門知識や能力が要求されます。クインタイルズではこのようなユニークな課題を理解するだけでなく、実証済みの解決方法を構築しています。 コンテンツは日本語です。
Read More
White Paper
China is now the world’s second largest pharmaceutical market, trailing only the United States.  Even with that size, its companies cannot ignore large Western and developing markets.  This paper examines Chinese biopharmaceutical companies with global growth aspirations – their typical strengths and weaknesses; how to leverage their “Asia advantage” in implementing global growth strategies; market access issues for Europe, the United States and Japan; and other success factors for Chinese companies to become global biopharma powerhouses.  Authors:  Geoff Garabedian, Senior Vice President and Managing Director, Quintiles Advisory Service  Christoph Schnorr, MD, Vice President, Quintiles Advisory Services Ling Zhen, JD, MBA, General Manager and Head of Greater China,...
Explore More
Press Release
RESEARCH TRIANGLE PARK, NC – May 4, 2015 – Quintiles today announced the expansion of its bioanalytical laboratory services with the establishment of a GLP-compliant bioanalytical liquid chromatography-mass spectrometry (LC-MS) laboratory. The laboratory, which is located in Oss, the Netherlands, will have extensive bioanalytical testing capabilities and will provide a European facility for Quintiles customers to conduct pharmacokinetics studies.  The Oss laboratory facility combines a cohort of employees with extensive industry experience, automated processes, and a state-of-the-art facility equipped to increase high-quality throughput. The new laboratory is led by Dr. Benno Ingelse, an industry expert with more than 15 years of (bio)analytical experience.  In addition, the Oss...
Read More
Press Release
Research Triangle Park, NC - Quintiles CFO Kevin Gordon will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015 in Las Vegas at the Encore Wynn. The Quintiles presentation will begin at 12:00 p.m. PDT. Investors may access a live audio webcast of the presentation on the Quintiles’ Investor Relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 33,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-75 best-selling drugs on the market....
Read More
Video 01:28
With Quintiles Patient-Centric Real-World Retention, you can retain patients throughout your real-world and late phase research while driving better reporting and compliance. Our expertise balances study design rigor with a differentiated and compelling patient experience. This is the player to use for single videos on Q.com...
White Paper
Emerging markets offer significant untapped sales potential for biopharma companies, but bringing a new product to these markets can be complicated, costly and time consuming. In this paper Evangelos Tryfonidis, Vice President of Business Development, Emerging Markets outlines the obstacles small and mid-sized biopharma companies face when entering emerging markets, the benefits and risks of different market access strategies, and how to choose an approach that delivers the most long term value to their business. Author: Evangelos Tryfonidis, Vice President of Business Development, Emerging...
Explore More
Fact Sheet
Healthcare systems across the globe are evolving as expenses rise alongside improvements in care, and the need to control costs becomes paramount. Payers are increasingly demanding proof of value from new medicines, raising the bar for compliance policies and requiring more evidence of patient impact. For today’s drug developers, the emphasis has shifted from “time to market” to “time to access.” By clearly communicating a strategic and cohesive value message to key stakeholders, the path to market access can be navigated more effectively and efficiently.  Discover how Medical Science Liaisons (MSLs) can be an integral part of your team and gain a deeper insight into:  The difference between a traditional sales representative and a MSL  How MSLs can help to prepare the market...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – May 1, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) announced today a proposed offering by its wholly owned subsidiary, Quintiles Transnational Corp. (“Quintiles Transnational”), of $800 million principal amount of senior unsecured notes due 2023 (the “Senior Notes”), subject to market and other conditions. The Senior Notes will be offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed new senior secured credit facility, to refinance its existing credit facilities, as well as for general corporate...
Read More
Presentation
Quintiles will be presenting 15 posters and presentations on real-world data, hybrid studies, biosimilars and...
Explore More
Fact Sheet
EA provides whole genome to focused set gene expression profiling and genotyping assays along with DNA and RNA sequencing services, sequence enrichment technologies and bioinformatics...
Read More
Fact Sheet
This Technical Note shows that advanced sample preparation and sequencing of RNA from FFPE samples produces similar results to samples that are...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – April 30, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to the InformationWeek Elite 100, a ranking of the top business technology innovators in the U.S. In compiling the InformationWeek Elite 100, the publication tracks the technology-based investments, strategies and results of some of the best-known organizations in the country.  Unique among corporate rankings, the Elite 100 spotlights the power of business technology innovation.  Quintiles was previously named to the InformationWeek 500 for five consecutive years. Accelerating the Clinical Trial Process:  Quintiles Infosario® Site Targeting Quintiles was named to the 2015 InformationWeek Elite 100 for its innovative Quintiles Infosario Site Targeting...
Read More
Brochure
At EA|Quintiles, you can rely on our experienced bioinformaticians to provide the analysis of RNA differential expression, variation and functional annotation for...
Read More
White Paper
The requirement for real-world evidence to support healthcare decision making has never been greater. This need, together with the increased availability of real-world data sources, has thrown light on the challenges of accessing and interpreting real-world data. Companies are looking for new approaches to gather real-world evidence at the right time, within the available budget, and to the appropriate quality standards. In this paper Louise Parmenter, Global Head of Operations, Epidemiology & Outcomes Research, Real-World & Late Phase Research and Anke van Engen, Principal, Advisory Services discuss strategies for success. Authors:  Louise Parmenter, Global Head of Operations, Epidemiology & Outcomes Research, Real-World & Late Phase Research at Quintiles Anke van Engen,...
Explore More
Fact Sheet
A patient-centric solution to provide stronger evidence Collecting patient-reported evidence for your observational studies is critical for demonstrating the safety and effectiveness of your therapies. To capture that data and produce a comprehensive picture of health outcomes, you need to engage patients over time and assist researchers in improving...
Read More
Scientific Poster
The authors undertook an observational, clinical study to explore the feasibility and potential clinical benefits of an upfront approach to the genomic profiling of tumors from metastatic colorectal cancer (mCRC)...
Explore More
Scientific Poster
VarPROWL is a great tool for detecting...
Explore More